The relationship between mortality and microbiological parameters in febrile neutropenic patients with hematological malignancies

References

1. ↵
   1. Tohamy ST,
   2. Aboshanab KM,
   3. El-Mahallawy HA,
   4. El-Ansary MR,
   5. Afifi SS

   (2018) Prevalence of multidrug-resistant Gram-negative pathogens isolated from febrile neutropenic cancer patients with bloodstream infections in Egypt and new synergistic antibiotic combinations. Infect Drug Resist 11:791–803.

   OpenUrl
2. ↵
   1. Forcina A,
   2. Lorentino F,
   3. Marasco V,
   4. Oltolini C,
   5. Marcatti M,
   6. Greco R,
   7. et al.

   (2018) Clinical Impact of Pretransplant Multidrug-Resistant Gram-Negative Colonization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:1476–1482.

   OpenUrl
3. ↵
   1. Hughes WT,
   2. Armstrong D,
   3. Bodey GP,
   4. Bow EJ,
   5. Brown AE,
   6. Calandra T,
   7. et al.

   (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   1. Infectious Diseases Society of Taiwan; Hematology Society of Taiwan; Medical Foundation in Memory Dr. Deh-Lin Cheng; Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education;CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccine

   (2005) Guidelines for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. J Microbiol Immunol Infect 38:455–457.

   OpenUrlPubMed
5. ↵
   1. Akova M,
   2. Paesmans M,
   3. Calandra T,
   4. Viscoli C

   (2005) International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer. A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer. Clin Infect Dis 40:239–245.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Jarque I,
   2. Salavert M,
   3. Sanz MA

   (2005) [Management of febrile neutropenic patients]. Enferm Infecc Microbiol Clin 23:24–29, Spanish.

   OpenUrl
7. ↵
   1. Sharma A,
   2. Lokeshwar N

   (2005) Febrile neutropenia in haematological malignancies. J Postgrad Med 51:S42–S48.

   OpenUrlPubMed
8. ↵
   1. Tamura K

   (2005) Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. Int J Antimicrob Agents 26:S123–S127, discussion S133-S140.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Pizzo PA

   (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323–1332.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Viscoli C

    (1998) The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother 41:65–80.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Trecarichi EM,
    2. Pagano L,
    3. Candoni A,
    4. Pastore D,
    5. Cattaneo C,
    6. Fanci R,
    7. et al.

    (2015) Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect 21:337–343.

    OpenUrlCrossRefPubMed
12. ↵
    1. Young SD,
    2. Feld R

    (1998) Fever associated with chemotherapy-induced neutropenia: a review of current therapeutic approaches. Curr Opin Infect Dis 11:401–409.

    OpenUrlPubMed
13. ↵
    1. D'Antonio D,
    2. Staniscia T,
    3. Piccolomini R,
    4. Fioritoni G,
    5. Rotolo S,
    6. Parruti G,
    7. et al.

    (2004) Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation. Chemotherapy 50:81–87.

    OpenUrlCrossRefPubMed
14. ↵
    1. Maschmeyer G,
    2. Haas A

    (2008) The epidemiology and treatment of infections in cancer patients. Int J Antimicrob Agents 31:193–197.

    OpenUrlCrossRefPubMed
15. ↵
    1. Sipsas NV,
    2. Bodey GP,
    3. Kontoyiannis DP

    (2005) Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 103:1103–1113.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    1. Tamura K,
    2. Imajo K,
    3. Akiyama N,
    4. Suzuki K,
    5. Urabe A,
    6. Ohyashiki K,
    7. et al.

    (2004) Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clin Infect Dis 39:S15–S24.

    OpenUrlCrossRefPubMed
17. ↵
    1. Serefhanoglu K,
    2. Ersoy Y,
    3. Serefhanoglu S,
    4. Aydogdu I,
    5. Kuku I,
    6. Kaya E

    (2006) Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia. Ann Acad Med Singapore 35:11–16.

    OpenUrlPubMedWeb of Science
18. ↵
    1. Rossini F,
    2. Terruzzi E,
    3. Verga L,
    4. Larocca A,
    5. Marinoni S,
    6. Miccolis I,
    7. et al.

    (2005) A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. Support Care Cancer 13:387–392.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    1. Gedik H,
    2. Simşek F,
    3. Kantürk A,
    4. Yildirmak T,
    5. Arica D,
    6. Aydin D,
    7. et al.

    (2014) Bloodstream infections in patients with hematological malignancies: which is more fatal - cancer or resistant pathogens? Ther Clin Risk Manag 10:743–752.

    OpenUrlPubMed
20. ↵
    1. Kang CI,
    2. Chung DR,
    3. Ko KS,
    4. Peck KR,
    5. Song JH,
    6. Korean Network for Study of Infectious Diseases

    (2012) Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 91:115–121.

    OpenUrlCrossRefPubMed
21. ↵
    1. Cornejo-Juárez P,
    2. Vilar-Compte D,
    3. Pérez-Jiménez C,
    4. Ñamendys-Silva SA,
    5. Sandoval-Hernández S,
    6. Volkow-Fernández P

    (2015) The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit. Int J Infect Dis 31:31–34.

    OpenUrlCrossRefPubMed
22. ↵
    1. Kim SH,
    2. Kwon JC,
    3. Choi SM,
    4. Lee DG,
    5. Park SH,
    6. Choi JH,
    7. et al.

    (2013) Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome. Ann Hematol 92:533–541.

    OpenUrlCrossRefPubMed
23. ↵
    1. Ha YE,
    2. Kang CI,
    3. Cha MK,
    4. Park SY,
    5. Wi YM,
    6. Chung DR,
    7. et al.

    (2013) Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents 42:403–409.

    OpenUrlCrossRef